TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 ( PDE5 ) with an IC 50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).
Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Phosphodiesterase (PDE)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.